Current Studies

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)
Samuel Dagogo-Jack, MD (PI); Ibiye Owei, MBBS- Study Coordinator
Sponsor: NIH
Participants are healthy individuals with either one or both parents with type 2 diabetes, age group 18-65
Recruitment is closed
Contact: Ann Ammons (901) 448-5299; dammons1@uthsc.edu

Effects of macronutrients on metabolic parameters in prediabetic women (Diet Study)
Abbas Kitabchi, MD (PI); Frankie Stentz, PhD- Study Coordinator
Sponsor: American Diabetes Association
Participants are obese women and men with prediabetes (IGT)
Recruitment open
Contact: (901) 448-5803; fstentz@uthsc.edu

Liraglitide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER)
Sam Dagogo-Jack, MD (PI); Haiming Du, MD- Study Coordinator
Sponsor: Novo Nordisk
Participants are Type 2 diabetic, H/O cardiovascular disease, age = 50 years with a HbA1c = 7.0%
Recruitment is closed
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu

CAROLINA Trial
Sam Dagogo-Jack, MD (PI); Helmut Steinberg, MD - Study Coordinator
Sponsor: Boehringer Ingelheim
Type of patients for recruitment: Type 2 diabetes, H/O cardiovascular disease (previous vascular disease or evidence of vascular related end-organ damage), age = 40 and =85 years, high risk of cardiovascular events, with HbA1c 6.5-8.5% (treatment naïve) or 6.5-7.5% (treated)
Recruitment is Open
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu

Development of Genotyping Assay for Identifying Prediabetes Risk (Genomic Study)
Samuel Dagogo-Jack, MD (PI); Haiming Du, MD-Study Coordinator Type of patients for recruitment: Caucasian or African American, 18-65 years old, without a current diagnosis of diabetes, No current use of medications known to alter blood glucose levels
Recruitment is Open
Contact: (901) 448-1024; hdu@uthsc.edu

Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA)
Sam Dagogo-Jack, MD (PI); Aidar Gosmanov, MD - Study Coordinator
Sponsor: Sanofi Aventis
Type of patients being recruited: men or women who experience a spontaneous ACS event and have H/O type 2 diabetes prior to screening visit with a HbA1c 5.5-11%
Recruitment is Open
Contact (901) 448-5318; gmazhar@uthsc.edu

Epidemiology of Diabetes Interventions and Complications Study (EDIC)
Sam Dagogo-Jack, MD, FRCP (PI); Christine S. Wigley R.N. - Study Coordinator
Sponsor: NIH
Division of Endocrinology, Diabetes, and Metabolism
Participants are type 1 diabetics from the Diabetes Control and Complications Trial (DCCT)
Recruitment: Closed
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-7942 E-mail: cwigley@uthsc.edu

Diabetes Prevention Program Outcomes Study (DPPOS)
Samuel Dagogo-Jack, MD (PI); Debbie Clark, RN - Study Coordinator
Sponsor: NIH/NIDDK
Participants of all races who had Impaired Glucose Tolerance between the ages of 25 with no upper age limit with a BMI of >24
Recruitment: Closed
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-2689; (fax) (901) 448-1592; dmclark@uthsc.edu

Look AHEAD Study, Action for Health in Diabetes (Look AHEAD)
Karen Johnson, MD, MPH, (PI); Abbas E. Kitabchi, PhD, MD, (Co-PI); Samuel Dagogo-Jack, MD (Co-PI); Carolyn Gresham, RN - Study Coordinator
Sponsor: NIDDK
Division of Endocrinology, Diabetes, and Metabolism
Participants are overweight individuals with Type 2 diabetes
Recruitment: Closed
Location: 920 Madison Ave. Suite 300A, Memphis, TN 38163
Contact: (901) 448-4787; cgresha1@uthsc.edu

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE)
Samuel Dagogo-Jack, MD (PI); James Ekwensi, MD - Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Recruitment is open
Contact: (901) 448-2676, jekwensi@uthsc.edu

The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)
Ebenezer Nyenwe, MD (PI), Helmut Steinberg, MD-Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Recruitment is open
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu

A long-term, randomized, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN)
Samuel Dagogo-Jack, MD (PI); Haiming Du, MD- Study Coordinator
Participants are Type 2 Diabetes with Cardiovascular Disease
Recruitment is open
Contact: Amy Bell, (901) 448-1008; asbell@uthsc.edu

Contact Us

920 Madison Avenue
Suite 300A
Memphis, Tennessee 38163
Tel: 901-448-2610
Fax: 901-448-4340
Email: sdj@uthsc.edu